Repligen (NASDAQ:RGEN) Downgraded by StockNews.com to “Sell”

StockNews.com lowered shares of Repligen (NASDAQ:RGEN) from a hold rating to a sell rating in a research note published on Thursday morning.

Other equities research analysts have also recently issued reports about the stock. Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday. They issued a “hold” rating and a $165.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Wolfe Research initiated coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday. They issued a “hold” rating and a $165.00 price objective for the company. Finally, Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $185.20.

Repligen Stock Down 0.5 %

Repligen stock opened at $146.54 on Thursday. The stock has a market cap of $8.21 billion, a PE ratio of -396.04, a P/E/G ratio of 4.64 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock’s fifty day moving average is $144.07 and its two-hundred day moving average is $141.81. Repligen has a 1-year low of $113.50 and a 1-year high of $211.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same period in the prior year, the company posted $0.23 earnings per share. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, sell-side analysts expect that Repligen will post 1.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Andra AP fonden purchased a new stake in Repligen in the 2nd quarter valued at approximately $25,000. International Assets Investment Management LLC purchased a new stake in shares of Repligen in the second quarter valued at approximately $33,000. UMB Bank n.a. grew its holdings in Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 130 shares during the period. Blue Trust Inc. raised its position in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares in the last quarter. Finally, Resources Management Corp CT ADV acquired a new stake in Repligen in the third quarter valued at $37,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.